ARS Pharmaceuticals Return on Equity

ARS Pharmaceuticals (SPRY) currently reports a ROE of -1721.8%. That is below the Healthcare sector average of 11.15%. Use the charts on this page to explore ARS Pharmaceuticals's ROE history and peer comparisons.

ARS Pharmaceuticals's ROE of -1721.8% is lower than the Healthcare sector average of 11.15%. That is roughly 15536.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but ARS Pharmaceuticals's current -1721.8% should be judged against Healthcare norms (sector average: 11.15%) and against SPRY's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -1721.8%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 11.15%. From there, open related valuation or income-statement pages for ARS Pharmaceuticals, and consider following SPRY for alerts when major investors trade the stock.

ARS Pharmaceuticals is classified in the Healthcare sector. On ROE, it currently shows -1721.8% versus a sector average near 11.15%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SPRY with unrelated industries.